Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03913039 · ClinicalTrials.gov registry record
Reduction of Prostate Biopsy Morbidity
A clinical trial of Prostate Cancer, sponsored by Maimonides Medical Center.
- Completed
- Registry status
- 157
- Enrollment target
- 1
- Study location
NCT03913039 is a study of Prostate Cancer that has completed, run by Maimonides Medical Center. The registered enrollment target is 157 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03913039, a study of Prostate Cancer, has completed, sponsored by Maimonides Medical Center.
- COMPLETED
- Registry status
- 157 participants
- Enrollment target
- 1
- Study location
Study Summary
Prostate biopsy is typically performed via either the transrectal or transperineal approach. This study is a case-control study being done to determine if a novel prostate biopsy protocol incorporating a transperineal approach, rectal swab to detect resistant bacteria and broad antibiotic prophylaxis will reduce infectious complications and hospital readmission compared to current biopsy practices.
Conditions Studied
Interventions
- PROCEDURE Transperineal biopsy Protocol
Study Locations (1)
New York
- Maimonides Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03913039
The ClinicalTrials.gov registry entry for NCT03913039 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower). The listed sponsor is Maimonides Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Transperineal biopsy Protocol is the first listed.
NCT03913039 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03913039 about?
NCT03913039 is a clinical study titled "Reduction of Prostate Biopsy Morbidity". Prostate biopsy is typically performed via either the transrectal or transperineal approach. This study is a case-control study being done to determine if a novel prostate biopsy protocol incorporating a transperineal approach, rectal swab to detect resistant bacteria and broad antibiotic prophylaxi...
What is the current status of trial NCT03913039?
This trial is currently completed. The enrollment target is 157 participants. The study started on 2019-05-01. Estimated completion is 2021-12-31.
What conditions does trial NCT03913039 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03913039?
The interventions under investigation include: Transperineal biopsy Protocol (PROCEDURE).
Who is sponsoring clinical trial NCT03913039?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03913039 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.